The mechanisms underlying EGFR–TKI resistance in NSCLC can be broadly categorized into acquired resistance following EGFR–TKI treatment and primary resistance characterized by cancer cells relying on alternative oncogenes like KRAS. The gene discussed is EGFR; the disease is cancer.